1 BTC
=
- USD
Reviva Pharmaceuticals Holdings, Inc. Common Stock
As of May 30, 2026 at 24:05 UTC
Chart
About Reviva Pharmaceuticals Holdings, Inc. Common Stock
Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063), which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, and Parkinson's disease psychosis, and its other drug candidate is RP1208.
Market Statistics
Trading Metrics
How to Buy RVPH
Create Your Account
Sign up, deposit BTC, and transfer it to your Unified Trading Account. It only takes a moment.
Start Your Trade
From Terminal, click Trade Now on the asset you want to buy. You'll be purchasing its tokenized asset.
Buy RVPH
Enter the amount and confirm your purchase. That's it! You'll see the impact of the trade in your Unified Trading Account.
New to Tokenized Assets? Learn more in our Help Center.
Latest News
5 articlesReviva Pharmaceuticals (NASDAQ: RVPH) closed a $10 million public offering on March 20, 2026, selling 6.67 million shares at $1.50 per share along with Series G and H warrants. The company plans to use proceeds for R&D activities, including the RECOVER-2 Phase 3 trial for brilaroxazine in schizophrenia treatment. Post-offering, Reviva has approximately $23 million in cash, expected to fund operations into Q1 2027.
Reviva Pharmaceuticals (NASDAQ: RVPH) announced the pricing of a $10 million public offering, selling 6.67 million shares at $1.50 per share along with Series G and H warrants. The company plans to use net proceeds to fund its RECOVER-2 Phase 3 trial for brilaroxazine in schizophrenia and general corporate purposes. The offering is expected to close on March 20, 2026.
Reviva Pharmaceuticals announced a public offering of 6.67 million shares at $1.50 per share with accompanying warrants, raising approximately $10 million in gross proceeds. The company plans to use the funds to support research and development activities, including its RECOVER-2 Phase 3 trial for brilaroxazine in schizophrenia treatment, along with working capital and general corporate purposes.
Reviva Pharmaceuticals Holdings, Inc. announced that its Founder, President, and CEO Laxminarayan Bhat will present at the Sachs 9th Annual Neuroscience Innovation Forum on January 11, 2026, in San Francisco. The late-stage biopharmaceutical company is developing therapies for CNS, inflammatory, and cardiometabolic diseases, with two main drug candidates: brilaroxazine (RP5063) and RP1208.
